CTKBCTKBHealthcare · Medical Devices

CTKB Stock Forecast: Cytek Biosciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$6.12
−3.16% on the day

The 3 Wall Street analysts covering Cytek Biosciences, Inc. hold a median 12-month price target of $7 — +14.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 95 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$826.6M
Ticker Nerd rank
95/ 100
Median analyst target
$7.00
Analysts covering
3
Revenue$48.1M+5.6% y/y
Operating income−$11.4M
Net income−$12.2M
Free cash flow−$877K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.8%
1M
+14.6%
YTD
+21.2%
1Y
+17.5%
From 52W high
−3.2%
From 52W low
+82.4%
$3.36
$6.32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Cytek Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
95/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
92
Accruals
92
Momentum
88
Volatility
86
Issuance
72
Value
70
Quality
53
Growth
43

Revisions (92): Analysts have, on balance, been raising their forecasts.

Growth (43): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CTKB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTKB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$3.00$4.00$5.00$6.00$7.00$8.00Jan 26Apr 26Jul 26Oct 26CTKBHigh $7.50Median $7.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2
Buy
1
Hold
0
Sell
$5.00
Low
$7.00
Median
$7.50
High

The green dot is the last close — the median target sits +14.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
10 Nov 2026Stephens & Co.MaintainsOverweight$6.00 → $7.00
13 May 2026Stephens & Co.MaintainsOverweight$5.50 → $4.75
12 May 2026Morgan StanleyMaintainsEqual-Weight$6.00 → $5.50
8 Jan 2026TD CowenMaintainsBuy—
11 Nov 2025Piper SandlerMaintainsOverweight—
28 May 2025Morgan StanleyMaintainsEqual-Weight—
12 May 2025Goldman SachsMaintainsSell—
19 Mar 2025Stephens & Co.ReiteratesOverweight—
4 Mar 2025Piper SandlerMaintainsOverweight—
11 Nov 2024Piper SandlerMaintainsOverweight—
13 Aug 2024Piper SandlerMaintainsOverweight—
13 May 2024Piper SandlerMaintainsOverweight—
6 Mar 2024Piper SandlerMaintainsOverweight—
29 Feb 2024Goldman SachsMaintainsBuy—
14 Dec 2023Stephens & Co.InitiatesOverweight—
9 Nov 2023Morgan StanleyMaintainsEqual-Weight—
24 Oct 2023Morgan StanleyMaintainsEqual-Weight—
16 Oct 2023Piper SandlerMaintainsOverweight—
19 July 2023Raymond JamesInitiatesMarket Perform—
11 May 2023Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CTKB.

Market Radar

This page is one stock. Monday covers all of them.

CTKB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CTKB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Cytek Biosciences, Inc. returned +17.5% against +6.9% for the S&P 500, dividends included.

CTKB vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26CTKBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CTKB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
3.9×

Cheaper than 27% of US stocks

Price / book
2.5×

Cheaper than 36% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
1.8%

Higher than 32% of US stocks

Earnings growth (YoY)
—
Gross margin
58.9%

Higher than 72% of US stocks

Operating margin
−22.5%

Higher than 22% of US stocks

Net margin
−39.1%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−23.2%

Higher than 31% of US stocks

Return on assets
−6.2%

Higher than 31% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cytek Biosciences, Inc. has a market value of $826.6M and an enterprise value of $595.3M.

  • Revenue in the twelve months to 30 June 2026: $206.7M. The latest quarter grew 5.6% year on year.

  • Net income over the same four quarters: −$80.6M, a −39.0% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.62.

  • Free cash flow in the twelve months to 30 June 2026: −$12.2M.

  • Cytek Biosciences, Inc. spent $63K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 130.0M.

  • forward P/E: 88.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Cytek Biosciences, Inc. employs 703 people — $294K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CTKB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CTKBCytek Biosciences, Inc.$826.6M95
VREXVarex Imaging Corp.$758.7M81
KIDSOrthoPediatrics Corp.$828.7M84
BVSBioventus, Inc.$832.5M93
INMDInMode Ltd.$713.9M85
AORTArtivion, Inc.$885.4M31
BBNXBeta Bionics, Inc.$703.3M29

Take a look at CTKB’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Cytek Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CTKB

What is the CTKB stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Cytek Biosciences, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $7.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTKB stock a buy right now?

Of the 3 analysts covering Cytek Biosciences, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cytek Biosciences, Inc. 95 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTKB?

As at 21 Nov 2026, Cytek Biosciences, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).

Will CTKB stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +14.4% from the last close, and Ticker Nerd's factor model ranks Cytek Biosciences, Inc. 95 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTKB stock forecast for 2030?

No analyst covering Cytek Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTKB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $7.5 over the next 12 months.

How has CTKB stock performed over the past year?

Cytek Biosciences, Inc. returned +17.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cytek Biosciences, Inc. do?

Cytek Biosciences, Inc. is a cell analysis solutions company that develops and markets advanced flow cytometry systems, reagents, software, and services for biomedical research and clinical applications. The company’s portfolio centers on its Full Spectrum Profiling technology, which supports high-resolution, high-content, and high-sensitivity analysis of single cells.

Company

About Cytek Biosciences, Inc.

Cytek Biosciences, Inc. is a cell analysis solutions company that develops and markets advanced flow cytometry systems, reagents, software, and services for biomedical research and clinical applications. The company’s portfolio centers on its Full Spectrum Profiling technology, which supports high-resolution, high-content, and high-sensitivity analysis of single cells. Its current product lineup includes the Aurora and Northern Lights cell analyzers, the Aurora CS cell sorter, and related integrated tools designed to help researchers study complex biological samples. Cytek Biosciences also offers conventional flow and image-based flow cytometry products through its acquired Amnis and Guava businesses, expanding its reach across cell analysis workflows. The company serves life science researchers and clinical laboratories with solutions used in areas such as immunology, cancer research, infectious disease, and inflammatory disease studies. Headquartered in Fremont, California, Cytek Biosciences focuses on providing a comprehensive platform for cell analysis in global research and applied science markets.

CEO Dr. Wenbin Jiang Ph.D. · 703 employees · United States · https://cytekbio.com